Skip to content

Study · Non-randomized trial · 1994

3 results

[The clinico-neurophysiological study of the effect of cerebrolysin on brain function in the acute and early recovery periods of hemispheric ischemic stroke].

Gusev EI, Burd GS, Gekht AB, Skvortsova VI, Bogomolova MA, Selikhova MV, Fidler SM

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 1994

PMID8009944 (opens in a new tab)PepBankPUB-08009944
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, the highest effect of Cerebrolysin occurred in patients with moderate severity.

    In plain wordsIn acute stroke, Cerebrolysin showed its greatest effect in patients with moderate severity.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedTreatment effect by acute stroke severity
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    10, 20 and 30 ml daily · 5 daysAs given in this study (human).

    Source sentences

    Summary
    In acute stroke the highest effect occurred in the affection of moderate severity.
    2 context sentences
    Summary · context
    Thirty patients with acute ischemic stroke and at early terms of postapoplectic recovery received cerebrolysin in daily doses 10, 20 and 30 ml for 5 days or 10 ml, i. v. for 10 days, respectively.
    Summary · context
    The patients were examined for neurological status and cerebral function.
  2. 02HumanNon-randomized trialEfficacy outcome

    In severe ischemic stroke, impaired functions tended to recover faster with Cerebrolysin than in control subjects.

    In plain wordsIn severe stroke, impaired functions tended to recover faster with Cerebrolysin than in control subjects.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseRecovery of impaired functions in severe stroke
    Study

    n: not reported in source

    Comparator
    Control subjects
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    10, 20 and 30 ml daily · 5 daysAs given in this study (human).

    Source sentences

    Summary
    In severe stroke the drug stimulated recovery of impaired functions which tended to restore more quickly than in control subjects.
    2 context sentences
    Summary · context
    Thirty patients with acute ischemic stroke and at early terms of postapoplectic recovery received cerebrolysin in daily doses 10, 20 and 30 ml for 5 days or 10 ml, i. v. for 10 days, respectively.
    Summary · context
    The patients were examined for neurological status and cerebral function.
  3. 03HumanNon-randomized trialEfficacy outcome

    In early convalescence after ischemic stroke, Cerebrolysin improved motor functions.

    In plain wordsIn patients recovering from stroke, Cerebrolysin improved motor functions.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMotor function in early convalescence
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    10 ml daily · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    In early convalescents cerebrolysin improved motor functions.
    2 context sentences
    Summary · context
    Thirty patients with acute ischemic stroke and at early terms of postapoplectic recovery received cerebrolysin in daily doses 10, 20 and 30 ml for 5 days or 10 ml, i. v. for 10 days, respectively.
    Summary · context
    The patients were examined for neurological status and cerebral function.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.